Table 2. . Survival estimates with 95% CIs at specific time points.

Group	30-day OS, 95% CI	90-day OS, 95% CI	1-year OS, 95% CI
10-day decitabine	66% (47–79%)	59% (40–74%)	22% (9–39%)
Low-intensity treatment	57% (42–70%)	32% (19–45%)	11% (4–21%)
High-intensity treatment	87% (80–92%)	66% (57–73%)	41% (32–49%)
All patients	70% (64–76%)	52% (45–58%)	27% (22–33%)
All patients >2011	70% (60–78%)	59% (48–68%)	32% (23–42%)

Overall, there was a statistically significant difference between the three groups (p < 0.001); specifically the groups that were different include low versus high-intensity treatment groups (p < 0.001).

OS: Overall survival.